Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
152 hedge funds and large institutions have $991M invested in Esperion Therapeutics in 2019 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 49 increasing their positions, 50 reducing their positions, and 30 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
31% more call options, than puts
Call options by funds: $23.3M | Put options by funds: $17.8M
2% less repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 50
6.2% less ownership
Funds ownership: 105.68% → 99.48% (-6.2%)
9% less funds holding
Funds holding: 167 → 152 (-15)
25% less capital invested
Capital invested by funds: $1.32B → $991M (-$333M)
50% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.7M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$14M |
| 3 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
+$9.66M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$7.29M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$7.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$72.3M |
| 2 |
SIM
Spark Investment Management
New York
|
-$7.52M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$6.14M |
| 4 |
State Street
Boston,
Massachusetts
|
-$5.97M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$5.88M |
ESPR Hedge Fund Activity: Q3 2019 in Review
152 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q3 2019, worth a combined $991M — down 25% from $1.32B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of ESPR and 15 opened new positions — a net loss of 15 holders — while 50 trimmed existing stakes and 49 added.
The largest buyer was Vanguard Group, adding an estimated $16.7M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $72.3M sold.
- 152 institutional investors held Esperion Therapeutics (ESPR) as of Q3 2019, down from 167 in Q2 2019.
- Funds reported $991M of Esperion Therapeutics stock for Q3 2019, down 25% quarter-over-quarter.
- 15 funds opened new Esperion Therapeutics positions in Q3 2019 and 30 closed out, a net change of -15 holders.
- The largest Esperion Therapeutics buyer in Q3 2019 was Vanguard Group, an estimated $16.7M added.
- The largest Esperion Therapeutics seller in Q3 2019 was PFM Health Sciences, an estimated $72.3M sold.
Based on aggregated 13F filings for Q3 2019.